Invex Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2020
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	2020
Other Revenue	1.21	1.21	0.46	0.18	-	-	Upgrade
Revenue	1.21	1.21	0.46	0.18	-	-	Upgrade
Revenue Growth (YoY)	9856.93%	164.06%	151.90%	-	-	-	Upgrade
Gross Profit	1.21	1.21	0.46	0.18	-	-	Upgrade
Selling, General & Admin	0.92	1.17	1.12	0.9	0.74	0.67	Upgrade
Research & Development	0.37	2.04	7.4	2.96	1.14	1.59	Upgrade
Operating Expenses	1.33	3.35	9.01	4.22	2.44	3.25	Upgrade
Operating Income	-0.12	-2.13	-8.55	-4.03	-2.44	-3.25	Upgrade
Interest & Investment Income	0.23	0.49	0.8	0.08	0.16	0.17	Upgrade
Other Non Operating Income (Expenses)	-0	-	-	-	0	-0.16	Upgrade
EBT Excluding Unusual Items	0.11	-1.64	-7.75	-3.95	-2.28	-3.24	Upgrade
Asset Writedown	-	-	-	-	-	-0.12	Upgrade
Pretax Income	0.11	-1.64	-7.75	-3.95	-2.28	-3.36	Upgrade
Net Income	0.11	-1.64	-7.75	-3.95	-2.28	-3.36	Upgrade
Net Income to Common	0.11	-1.64	-7.75	-3.95	-2.28	-3.36	Upgrade
Shares Outstanding (Basic)	76	75	75	75	75	56	Upgrade
Shares Outstanding (Diluted)	76	75	75	75	75	56	Upgrade
Shares Change (YoY)	0.62%	0.19%	0.02%	0.03%	33.77%	138.02%	Upgrade
EPS (Basic)	0.00	-0.02	-0.10	-0.05	-0.03	-0.06	Upgrade
EPS (Diluted)	0.00	-0.02	-0.10	-0.05	-0.03	-0.06	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-	Upgrade
Operating Margin	-9.61%	-176.00%	-1861.73%	-2212.89%	-	-	Upgrade
Profit Margin	9.43%	-135.43%	-1688.11%	-2169.06%	-	-	Upgrade
EBIT	-0.12	-2.13	-8.55	-4.03	-2.44	-3.25	Upgrade
EBIT Margin	-9.61%	-176.00%	-	-	-	-	Upgrade

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.